View stunning SlideShares in full-screen with the new iOS app!Introducing SlideShare for AndroidExplore all your favorite topics in the SlideShare appGet the SlideShare app to Save for Later — even offline
View stunning SlideShares in full-screen with the new Android app!View stunning SlideShares in full-screen with the new iOS app!
FOR IMMEDIATE RELEASEMEDIA CONTACTS: AUA Media Relations: 410-689-3932 Wendy Waldsachs Isett (cell): 410-977-4770 AUA ANNOUNCES 2011 ANNUAL AWARD WINNERS Awards Recognize Top Urologists, Honor Service to Specialty and SocietyLINTHICUM, MD, January 18, 2011–The American Urological Association today announced the list of2011 award recipients who will be honored at the Association’s upcoming Annual Meeting inWashington, DC, this May. These physician researchers and educators are being honored for theircontributions to the field of medicine, the specialty of urology, and the AUA.The following awards will be presented:Ramon Guiteras Award: The Ramon Guiteras Award is presented annually to an individual who isdeemed to have made outstanding contributions to the art and science of urology. E. DarracottVaughan Jr., MD, will receive this award for outstanding contributions to the science of urology, mostnotably in the pathophysiology of renal obstruction, adrenal disease and benign prostatic hyperplasia(BPH).Hugh Hampton Young Award: The Hugh Hampton Young Award is presented annually to an individualfor outstanding contributions to the study of genitourinary tract disease. William D. Steers, MD, willreceive this award for his outstanding contributions in urological education and pharmacology of thegenitourinary tract, including female urology, urinary incontinence and neurogenic bladder.Gold Cystoscope Award: The Gold Cystoscope Award is presented annually to a urologist distinguishedby outstanding contributions to the profession within 13 years of completing residency training. Sam S.Chang, MD, will receive this award for outstanding contributions in the field of bladder and prostatecancer, as well as the integration of evidence-based urological oncology into clinical pathways, practiceguidelines and the AUA Core Curriculum.Lifetime Achievement Award: The Lifetime Achievement Award is presented annually to an individualwho has been deemed to have made outstanding contributions to advance the mission and goals of theAUA. Arthur D. Smith, MD, will receive this award for lifetime dedication to the development of thefield of endourology.Victor A. Politano Award: The Victor A. Politano Award is presented annually to an individual foroutstanding research and work in the field of incontinence and for enhancing the treatment ofincontinent patients, thereby helping to improve their quality of life. George D. Webster, MD, willreceive this award in recognition of outstanding contributions in incontinence, female urology and
reconstructive surgery.William P. Didusch Art and History Award: The William P. Didusch Art and History Award promotes andrecognizes contributions to urological art, including, but not limited to, illustrations, sculpture, stillphotography, motion pictures and television productions. Robert Meyer, MD, will receive this award forhis outstanding photographic documentation and written contributions to urologic history in the UnitedStates and Canada.Distinguished Contribution Award: The Distinguished Contribution Awards are presented annually toindividuals who have made outstanding contributions to the science and practice of urology, including,but not limited to, contributions made in a sub-specialty area, for military career service or forhumanitarian efforts. Three AUA members will receive this award: Culley C. Carson III, MD, for outstanding contributions to the understanding and management of the urological aspects of sexual medicine Michael A. S. Jewett, MD, for outstanding contributions to the science and treatment of urological malignancies Anthony W. Middleton Jr., MD, for outstanding contributions in health policy, socioeconomics, managed care and survey analysis on the national, Section and state levelsDistinguished Service Awards: The Distinguished Service Awards are presented annually to individualswho are deemed to have made outstanding contributions to the goals of the AUA. The followingindividuals will receive this award: Richard K. Babayan, MD, for outstanding service to the AUA Foundation, AUA Leadership Program and the AUA Board of Directors Harris M. Nagler, MD, for outstanding contributions to the goals of the AUA through service as the chair of the Judicial & Ethics Committee Mark S. Litwin, MD, MPH, for outstanding contributions to the goals of the AUA through committee service and editorial contributions to urological publications, including the Urologic Diseases in America ProjectGold Cane Award: The Gold Cane Award is presented to a senior urologist distinguished by outstandingcontributions to the profession and to the AUA. David T. Uehling, MD, will receive this award for hisoutstanding contributions in investigations of urinary tract infections and clinical expertise in pediatricurology.Presidential Citations: Presidential Citations are presented to individuals deemed to have significantlypromoted the cause of urology during a specific period of time. Each recipient is chosen by the AUAPresident. Six Presidential Citations will be presented to honor the following individuals: Jack L. Sales, MD, for a lifetime of exemplary service to the American and Canadian Urological Associations and for establishing the CUA and Northeastern Section Foundations Ajit Gangadhar Phadke, MD, for outstanding contributions in establishing and fostering progressive international relations with the AUA Jorge Elias Dib, MD, for his dedication to urology in Mexico and fostering collaborations with the AUA through the South Central Section Frank J. DeSantis, CAE, for more than 45 years of outstanding administrative management of the AUA Western Section
Shlomo Raz, MD, for outstanding contributions in the field of female reconstructive surgery and strengthening urologic education in Mexico and South America Michael T. Sheppard, CPA, CAE for dedicated service as the Executive Director, advancing the AUA through new opportunities and leadership in navigating the complexities and challenges of association management“These awards are testimony to the work of individuals who have made significant contributions to oursubspecialty,” said AUA Awards Committee Chair Paul F. Schellhammer, MD. “We will be honored torecognize the recipients at our annual meeting in Washington DC.” About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, theAmerican Urological Association is the pre-eminent professional organization for urologists, with more than 16,000members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients. ###
#1481UTILIZATION OF NEPHRON-SPARING SURGERY AMONG RENAL CELL CARCINOMA PATIENTS WITHDIABETES OR HYPERTENSIONChristopher Filson*, David Miller, Ann Arbor, MI, Julie Ruterbusch, Detroit, MI, Joanne Colt, Wong-HoChow, Bethesda, MD, Kendra Schwartz, Detroit, MIIntroduction and Objectives: Nephron-sparing surgery (NSS) is the preferred treatment for patients withearly-stage kidney cancer and concurrent risk factors for chronic kidney disease (CKD). In this context,we used population-based data from National Cancer Institute’s U.S. Kidney Cancer Study (KCS) toevaluate whether receipt of NSS is more common among patients with renal cell carcinoma (RCC) andconcurrent diabetes mellitus (DM) or hypertension (HTN).Methods: The KCS is a population-based case–control study conducted in the metropolitan areas ofDetroit and Chicago from 2002-2007. During the study interval, 1,136 patients with kidney cancerconsented to both an epidemiological interview and medical record review. From these sources, weascertained detailed information regarding patient demographics, medical comorbidities, clinical andpathological characteristics of the kidney cancer, and treatment(s) received. We then used bivariatestatistical analyses to evaluate differences in the frequency of NSS among patients with or without DMor HTN, including analyses stratified by tumor size.Results: Our analytic cohort comprised 894 cases treated surgically for RCC. Among this group, 183patients (20.5%) underwent NSS; this proportion increased to 34.3% among cases with tumors ≤ 4 cm(p<0.01). Overall, 17% and 59% of patients in the analytic cohort had DM or HTN, respectively.Compared to patients with neither DM nor HTN, the use of NSS was similar for patients with DM alone(19% vs 16% if DM alone, p=0.65) or HTN alone (19% vs 20% if HTN alone, p=0.71); this finding wasconsistent among patients with tumors ≤ 4cm. However, patients with both HTN and DM weresignificantly more likely to receive NSS, compared to patients who did not have either diagnosis (28% vs19%, p=0.04, Figure).Conclusions: NSS is performed in up to one-third of patients with early-stage kidney cancer, and morefrequently among RCC patients with both DM and HTN. However, the finding that NSS is not appliedwith relatively greater frequency among patients with small renal tumors and important individual CKDrisk factors (DM or HTN alone) suggests an immediately-available opportunity to improve surgical carefor patients with RCC.Source of Funding: National Institutes of Health Intramural Research Program; The New York Academyof Medicine